Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response

J Eur Acad Dermatol Venereol. 2011 Aug;25(8):896-901. doi: 10.1111/j.1468-3083.2010.03877.x. Epub 2010 Nov 4.

Abstract

Background: Photodynamic therapy (PDT) is increasingly used in the treatment of basal cell carcinoma (BCC). However, scant information is available about the impact of both patient- and lesion-related characteristics on the effectiveness of therapy. Therefore, on the basis of the current data, it is difficult to draw clear-cut indications to use PDT for treatment of BCC in clinical practice.

Objective: To investigate the clinical and pathological determinants of response of BCC to PDT with methylaminolevulinate (MAL) and red light.

Methods: The clinical and pathological characteristics of 194 BCCs in 135 patients, treated with MAL-PDT, were evaluated. Lesions were treated with MAL-PDT according to established methods and the response was assessed by clinical follow-up of the patients.

Results: Complete response to PDT was 62%, with a better response for superficial BCC (95/116, 82%) than nodular BCC (26/78, 33%). When determinants of response were analysed, the nodular type and the location on the limbs emerged as significant clinical predictors of failure. Among the pathological characteristics, the nodular and infiltrative histotypes, as well as ulceration and tumour thickness were associated with a lower response to therapy. Patients' age and gender, as well as the size of the lesions, were not found to be significant predictors.

Conclusions: Optimization of PDT procedure for BCC requires a careful selection of the lesions. In particular, superficial BCCs, preferentially located on the trunk, show the best therapeutic response.

Publication types

  • Multicenter Study

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Aminolevulinic Acid / analogs & derivatives*
  • Aminolevulinic Acid / therapeutic use
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology*
  • Extremities / pathology
  • Female
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / pathology
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Retrospective Studies
  • Sex Factors
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology*
  • Torso / pathology
  • Treatment Outcome

Substances

  • Photosensitizing Agents
  • methyl 5-aminolevulinate
  • Aminolevulinic Acid